<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857998</url>
  </required_header>
  <id_info>
    <org_study_id>2015-523-00CH1</org_study_id>
    <nct_id>NCT02857998</nct_id>
  </id_info>
  <brief_title>A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms</brief_title>
  <official_title>A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523&#xD;
      in Patients With Relapsed or Refractory Mature B-cell Neoplasms&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion&#xD;
      stage (stage 2).&#xD;
&#xD;
      Dose-escalation stage (stage 1):&#xD;
&#xD;
      The conventional 3+3 design (3 patients per dose cohort, with the potential to add additional&#xD;
      3 patients to the same cohort to further evaluate toxicity) will be applied for dose&#xD;
      escalation and maximum tolerated dosage determination. Approximately 27 to 42 dose limited&#xD;
      toxicities evaluable patients will be enrolled. The actual number of patients depends on the&#xD;
      dose limited toxicities situation as well as the maximum tolerated dosage reached at this&#xD;
      stage.&#xD;
&#xD;
      Dosing will begin at 200mg once daily. A cycle of study treatment will be defined as 28 days&#xD;
      of continuous dosing.&#xD;
&#xD;
      Dose-expansion stage (stage 2):&#xD;
&#xD;
      This phase is to further evaluate the safety, the pharmacokinetics and anti-tumor activity of&#xD;
      HMPL-523 at recommended phase 2 dosage in approximately 190 patients with relapsed or&#xD;
      refractory Hematologic Malignancies.&#xD;
&#xD;
      In this stage, approximately 190 patients with Mature B-cell Neoplasms will be enrolled with&#xD;
      recommended phase 2 dosage 600milligram(mg) one a day(QD) as starting dosing. The tumor types&#xD;
      of the expansion stage are restricted to Chronic lymphocytic leukemia/ small lymphocytic&#xD;
      lymphoma (CLL/SLL), Mantle cell lymphoma (MCL), Follicular Lymphoma (FL), Diffuse large&#xD;
      B-cell lymphoma (DLBCL), Marginal zone lymphoma (MZL)and Waldenstrom's macroglobulinemia&#xD;
      (WM)/Lymphoplasmacytic lymphoma(LPL) Subjects will receive HMPL-523 with every 28-day&#xD;
      treatment cycle until disease progression, death, or intolerable toxicity, whichever comes&#xD;
      first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 27, 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limited toxicities evaluated with NCI CTCAE v4.03</measure>
    <time_frame>within 28 days after the first dose</time_frame>
    <description>Incidence of dose limited toxicities and associated dose of HMPL-523</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration calculated with Blood samples</measure>
    <time_frame>within 29 days after the first dose</time_frame>
    <description>Blood samples will be taken to measure the levels of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration calculated with Blood samples</measure>
    <time_frame>within 29 days after the first dose</time_frame>
    <description>Blood samples will be taken to measure the levels of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>within 30 days after the last dose</time_frame>
    <description>the proportion of subjects who have a Complete Response or Partial Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events evaluated by NCI CTCAE v4.03</measure>
    <time_frame>from the first dose to within 30 days after the last dose</time_frame>
    <description>Incidence of adverse events and associated dose of HMPL-523</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">217</enrollment>
  <condition>Mature B-cell Neoplasms</condition>
  <arm_group>
    <arm_group_label>HMPL-523</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration, at dose of 200, 400, 600 and 800 mg once daily;at dose of 200,300, 400mg twice daily at Dose-escalation stage; At Dose-expansion stage, if patients dosing at 600mgQD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMPL-523</intervention_name>
    <description>Oral administration, once daily</description>
    <arm_group_label>HMPL-523</arm_group_label>
    <other_name>HMPL-523 Acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent Form&#xD;
&#xD;
          2. Age &gt;=18 years&#xD;
&#xD;
          3. Histologically relapsed or refractory mature B-cell Neoplasms, have failed at least&#xD;
             one prior therapy or patients who are unable to tolerate standard therapy or no&#xD;
             curative therapy or therapy of higher priority exists&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group（ECOG） performance status of 0 or 1&#xD;
&#xD;
          5. Expected survival of more than 24 weeks as determined by the investigator&#xD;
&#xD;
          6. In expansion stage, Subjects should have at least one dual diameter measurable lesion&#xD;
             expect for subject with CLL or subject with LPL/WM with abonormal immunoglobulin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with primary central nervous system(CNS) lymphoma&#xD;
&#xD;
          2. Any of the following laboratory abnormalities:&#xD;
&#xD;
               -  Absolute neutrophil count&lt;1.5×109/L&#xD;
&#xD;
               -  Hemoglobin &lt;80g/L&#xD;
&#xD;
               -  Platelet&lt;75 ×109 /L&#xD;
&#xD;
          3. Inadequate organ function, defined by the following:&#xD;
&#xD;
               -  Total bilirubin &gt;1.5the ULN with the following exception:&#xD;
&#xD;
                    -  Patients with known Gilbert disease who have serum bilirubin level ≤3 the&#xD;
                       upper limit of normal(ULN) and normal Aspartate&#xD;
                       aminotransferase(AST)/Alanine aminotransferase(ALT) may be enrolled.&#xD;
&#xD;
          4. AST and/or ALT &gt; 2.5 the ULN with the following exception:Patients with documented&#xD;
             disease infiltration of the liver may have AST and/or ALT levels ≤ 5 the ULN.&#xD;
&#xD;
          5. Serum amylase or lipase &gt; the ULN&#xD;
&#xD;
          6. Serum creatinine &gt; 1.5 the ULN or estimated creatinine clearance &lt; 50 mL/min&#xD;
&#xD;
          7. International normalized ratio (INR)&gt;1.5 the ULN or activated partial thromboplastin&#xD;
             time (aPTT)&gt;1.5 the ULN&#xD;
&#xD;
          8. Clinically significant history of liver disease, including cirrhosis, current alcohol&#xD;
             abuse, or current known active infection with HIV, hepatitis B virus (HBV), or&#xD;
             hepatitis C virus (HCV)&#xD;
&#xD;
          9. Pregnant (positive pregnancy test) or lactating women&#xD;
&#xD;
         10. New York Heart Association (NYHA) Class II or greater congestive heart failure&#xD;
&#xD;
         11. Congenital long QT syndrome or corrected QT interval (QTc) &gt; 480 msec&#xD;
&#xD;
         12. Currently use medication known to cause QT prolongation.&#xD;
&#xD;
         13. Subjects with presence of clinically detectable second primary malignant tumors at&#xD;
             enrollment, or other malignant tumors within the last 2 years (with the exception of&#xD;
             radically treated basal cell or squamous cell carcinoma of the skin, in situ cervix,&#xD;
             or in situ breast cancer).&#xD;
&#xD;
         14. Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy,&#xD;
             or radiotherapy within 3 weeks prior to initiation of study treatment&#xD;
&#xD;
         15. Herbal therapy ≤1 week prior to initiation of study treatment&#xD;
&#xD;
         16. Prior treatment with any spleen tyrosine kinase (SYK) inhibitors (Fostamatinib)&#xD;
&#xD;
         17. Prior allogeneic stem cell transplant within 6 months prior to initiation of study&#xD;
             treatment or with any evidence of active graft versus host disease or requirement for&#xD;
             immunosuppressants within 28 days prior to initiation of study treatment&#xD;
&#xD;
         18. Clinically significant active infection (pneumonia)&#xD;
&#xD;
         19. Major surgical procedure within 4 weeks prior to initiation of study treatment&#xD;
&#xD;
         20. History of myocardial infarction or unstable angina within 6 months prior to&#xD;
             initiation of study treatment&#xD;
&#xD;
         21. Inability to take oral medication, prior surgical procedures affecting absorption, or&#xD;
             active peptic ulcer disease&#xD;
&#xD;
         22. Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1,&#xD;
             except for alopecia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Yang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hutchison Medipharma Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Yang, M.D.</last_name>
    <phone>+86 21 2067 3226</phone>
    <email>Weissy@hmplglobal.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Sun</last_name>
    <phone>+86 21 2067 3221</phone>
    <email>liangs@hmplglobal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BeijingCancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu</last_name>
      <email>zhujun@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Jun Zhu, MD.PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junning Cao</last_name>
      <email>cao_junning@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

